Lantern Pharma
LTRN
32 hedge funds and large institutions have $8M invested in Lantern Pharma in 2024 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 5 closing their positions.
700% more call options, than puts
Call options by funds: $16K | Put options by funds: $2K
63% more capital invested
Capital invested by funds: $4.9M → $8M (+$3.09M)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
10.76% more ownership
Funds ownership: 12.4% → 23.17% (+11%)
3% more funds holding
Funds holding: 31 → 32 (+1)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Voss Capital
Houston,
Texas
|
+$171K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$121K |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
+$51.4K |
| 4 |
SA
Sanctuary Advisors
Indianapolis,
Indiana
|
+$34.2K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$15.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$236K |
| 2 |
DC
Davenport & Co
Richmond,
Virginia
|
-$95.9K |
| 3 |
TAM
Tocqueville Asset Management
New York
|
-$62.4K |
| 4 |
Two Sigma Investments
New York
|
-$60.9K |
| 5 |
PWM
Perigon Wealth Management
San Francisco,
California
|
-$49K |
LTRN Hedge Fund Activity: Q4 2024 in Review
32 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q4 2024, worth a combined $8M — up 63% from $4.9M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new LTRN positions and 5 closed out — a net gain of 1 holder — while 8 added to existing stakes and 10 trimmed.
The largest buyer was Voss Capital, opening a new position worth an estimated $171K. The largest seller was NewEdge Advisors, cutting an estimated $236K.
- 32 institutional investors held Lantern Pharma (LTRN) as of Q4 2024, up from 31 in Q3 2024.
- Funds reported $8M of Lantern Pharma stock for Q4 2024, up 63% quarter-over-quarter.
- 6 funds opened new Lantern Pharma positions in Q4 2024 and 5 closed out, a net change of +1 holder.
- The largest Lantern Pharma buyer in Q4 2024 was Voss Capital, an estimated $171K added.
- The largest Lantern Pharma seller in Q4 2024 was NewEdge Advisors, an estimated $236K sold.
Based on aggregated 13F filings for Q4 2024.